200 related articles for article (PubMed ID: 19255893)
1. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.
Sanjula B; Shah FM; Javed A; Alka A
J Drug Target; 2009 Apr; 17(3):249-56. PubMed ID: 19255893
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
Venishetty VK; Chede R; Komuravelli R; Adepu L; Sistla R; Diwan PV
Colloids Surf B Biointerfaces; 2012 Jun; 95():1-9. PubMed ID: 22463845
[TBL] [Abstract][Full Text] [Related]
3. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration.
Shah MK; Madan P; Lin S
Pharm Dev Technol; 2014 Jun; 19(4):475-85. PubMed ID: 23697916
[TBL] [Abstract][Full Text] [Related]
4. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
5. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats.
Zhang WL; Liu JP; Liu XX; Chen ZQ
Yao Xue Xue Bao; 2009 Dec; 44(12):1421-8. PubMed ID: 21348419
[TBL] [Abstract][Full Text] [Related]
6. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate.
Chakraborty S; Shukla D; Vuddanda PR; Mishra B; Singh S
J Pharm Pharmacol; 2011 Jun; 63(6):774-9. PubMed ID: 21585374
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of carvedilol-loaded transdermal drug delivery system: In-vitro and in-vivo characterization study.
Kshirsagar SJ; Bhalekar MR; Mohapatra SK
Drug Dev Ind Pharm; 2012 Dec; 38(12):1530-7. PubMed ID: 22356303
[TBL] [Abstract][Full Text] [Related]
8. Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation.
Siram K; Chellan VR; Natarajan T; Krishnamoorthy B; Mohamed Ebrahim HR; Karanam V; Muthuswamy SS; Ranganathan HP
Expert Opin Drug Deliv; 2014 Sep; 11(9):1351-65. PubMed ID: 24847779
[TBL] [Abstract][Full Text] [Related]
9. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
[TBL] [Abstract][Full Text] [Related]
10. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU
Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
Kumar VV; Chandrasekar D; Ramakrishna S; Kishan V; Rao YM; Diwan PV
Int J Pharm; 2007 Apr; 335(1-2):167-175. PubMed ID: 17161566
[TBL] [Abstract][Full Text] [Related]
12. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.
Mishra A; Imam SS; Aqil M; Ahad A; Sultana Y; Ameeduzzafar ; Ali A
Drug Deliv; 2016 May; 23(4):1486-94. PubMed ID: 26978072
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles.
Varshosaz J; Minayian M; Moazen E
J Liposome Res; 2010 Jun; 20(2):115-23. PubMed ID: 19694503
[TBL] [Abstract][Full Text] [Related]
15. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
[TBL] [Abstract][Full Text] [Related]
16. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
[TBL] [Abstract][Full Text] [Related]
17. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
Singh B; Singh R; Bandyopadhyay S; Kapil R; Garg B
Colloids Surf B Biointerfaces; 2013 Jan; 101():465-74. PubMed ID: 23010056
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
Dudhipala N; Veerabrahma K
Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
[TBL] [Abstract][Full Text] [Related]
19. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach.
Makwana V; Jain R; Patel K; Nivsarkar M; Joshi A
Int J Pharm; 2015 Nov; 495(1):439-446. PubMed ID: 26367780
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
Manjunath K; Venkateswarlu V
J Control Release; 2005 Oct; 107(2):215-28. PubMed ID: 16014318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
